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Objective 
The authors' objective was to identify factors associated with candidemia and candidemia-reiated 
death among adult liver transplant reCIpients. 
Summary Background Data 
InvaSive candidiasIs IS the most common severe fungal Infection occurring arter liver 
transoiantatlon and IS assoc:ated With high mOffildity and mortality rates. Although candidemla IS 
not alwavs found dunng InvaSive candidiasIs. It has been conSidered as an indicator of InvaSive 
canaldlasls In Iffimunccomprcmlsed ~atientsK 
Methods 
A time-matched case-control study of 26 patiems with canoidemia, which was defined as the 
Isoiatlon of Candida from at least one blood culture, and 52 control patients without candlceffila 
was re~ortedK Two contml patients were matched With each case patient regarding time of 
transplantation and duration of follow-up. 
Results 
Between December 1985 and /JecerTt)er 1992. cardiderTlla developed in 1 .4% of adJt liver transpiant 
reaptef1ts a median of 25 days alter transo!antation (range, 2-1600 days). The overaI mortality rate 
among patler1ts wrth candidefTlia was 81 %, and 71 % at these deaths were related to candidema 
CondrtlonallogiStX: regre5SlOn analysis was used to dentify tactcrs assoaated wrth candidemia. whch 
were 1) hypergtycema treated WIth iflSUin 4J to 2 weeks betore candidemia (odds ralio [OR], 16.15; p 
= 0.(02), and 2) exposlJ'e to rTlC(e than three dfferent Iltravenous antDiotics before devebpment ot 
candldema (CR, 11.15: p = O.cX15). The vanabIes predidive of death related to candidema were 
abdcmnal surgery performed ~ to 1 week before candidemia (relative risk [RRJ, 7.25; p = 0.(2), tlgl 
>M'ute blood ceil count (RR. 1.10; P = 0,01), lower patelet count (RR, 0.99; p = 0.(2), and elevated AST 
wrth candldema (RR. 1.001: p = 0,01). 
Condusions 
Hypergycema that requi'es inSLiin and expoo..re to more than ttYee antbotics are the factcrs 
assoaated wrth the deveq:ment at candidemia n liver transplant reapients. When ca-ddemia 
develops sI"lor1ly alter abdcmnal 9Jgery and n patients wrtI1 eievated AST, high whte blood cell COLnt. 
or low patelet COLnt, it is assoaated wrth a high mataIity rate. 
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Invasive candidiasis is the most common severe fungal 
infection to occur after liver transplantation.! It is known 
to occur in patients who have difficult and prolonged sur-
gery, who are immunosupllfessed. and who have re-
ceived intensive antibiotic therapy,2-9 factors common 
to many liver transplant recipients. Development of in-
vasive candidiasis after liver transplantation is associated 
with a high mortality rate (70%)10.11 due to the difficulty 
in making an early diagnosis of the disease. 
The Candida species is not always found in the blood-
stream of patients with invasive candidiasis. However, 
candidemia has been considered a good indicator of dis-
seminated Candida infection among immunocompro-
mised patients. !2-14 In a recent study, fungemia due to C. 
albicans was associated with a poor prognosis compared 
with other Candida species. IS The authors concluded 
that even a single blood culture positive for Candida spe-
cies should raise the suspicion of invasive infection, par-
ticularly in immunocompromised hosts. IS 
The purpose of this retrospective matched case-con-
trol study was to identify factors associated with the de-
velopment of candidemia and candidemia-related mor-
tality among adult liver transplant recipients. Although 
several studies have identified risk factors for candidemia 
in different populations, none have involved its develop-
ment after liver transplantation. The number of liver 
transplants is increasing each year. and the optimum 
cost-benefit of transplantation will depend largely on 
prevention of infectious complications. such as candidi-
asiS. 
MATERIAL AND METHODS 
Patient Selection 
From December 1985 to December 1992, a total of 
197 adult patients developed candidemia at Presbyterian 
University Hospital in Pittsburgh. Of these, 36 (18.3%) 
were liver transplantation recipients. Complete medical 
records were available for 26 patients, who constituted 
the study group. During the same time period, a total of . 
2621 adult patients underwent liver transplantation at 
the same institution. To assemble a homogeneous con-
trol group with respect to duration of exposure to the 
risk factors, we selected for each candidemia patient two 
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control patients who were at risk for candidemia at the 
time each patient's condition was diagnosed. Control pa-
tients were matched with case patients with respect to 
time of transplantation and duration of follow-up to the 
day of the first blood culture indicative of Candida spe-
cies. A patient was not eligible to be a control patient if 
he or she did not survive at least as long as the matched 
case patient and if autopsy or another histologic speci-
men revealed invasive candidiasis. 
Definitions 
We defined candidemia as the isolation of Candida 
species from at least one blood culture. Candida endoph-
thalmitis was diagnosed when on evaluation by an oph-
thalmologist, the patient was found to have characteris-
tic lesions. Death related to candidemia was defined by 
autopsy findings showing invasive candidiasis or, if an 
autopsy was not performed, the patient's dying within 2 
weeks of development of candidemia. 
Microbiologic Studies 
Surveillance cultures for fungi were not performed sys-
tematically. However, specimens were submitted for 
fungal culture when any infectious complication was 
clinically suspected. 
Treatment and Immunosuppression 
Orthotopic liver transplantation was performed ac-
cording to the standard techniques described by Starzl et 
al. 16 Cefotaxime and ampicillin were administered intra-
venously as antibacterial prophylaxis for the first 3 days 
after transplantation. Nystatin (500,000 units four 
times/day) was given orally for Candida prophylaxis. In 
several cases involving difficult and prolonged surgery, 
low-dose amphotericin B ( 10-20 mg/day) administered 
intravenously was used for fungal prophylaxis, begin-
ning at the time of surgery and continuing for 2 to 4 
weeks. Primary prophylaxis for Pneumocystis carinii 
with trimethoprim-sulfamethoxazole was given rou-
tinely. 
Two immunosuppressive regimens were used. The 
first included cyciosporine A (Sandoz Co., East Hanover, 
NJ) and corticosteroids. Cyclosporine was initially ad-
ministered intravenously (3 mg,lkg/day). Oral cyclospor-
ine was initiated with the return of bowel function and 
was overlapped briefly with the intravenous dose. An in-
travenous intraoperative dose of I g methylprednisolone 
was followed by a 5-day tapering of the drug from 200 
mg to 20 mg. The second regimen included tacrolimus 
(FK506; Fujisawa Pharmaceutical Co, Osalca. Japan) 
and corticosteroids. Tacrolimus was started intrave-
,. 
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nously (0.05-0.1 mg/kg/day) and was converted to an 
oral dose of 3 mg/kg/day with the return of bowel func-
tion. An intraoperative dose of I g methylprednisolone 
administered intravenously was f()llowed by low~ose 
corticosteroids (20 mg/day) beginning immediately after 
transplantation. Subsequent adjustments of the immu-
nosuppressive dose were guided by the quality of the 
graft. the presence of rejection. toxicity. and cydospor-
ine/tacrolimus plasma trough levels. Azathioprine was 
also administered to some case patients. Rejection epi-
sodes occurring with the use of either regimen were 
treated with increased doses of corticosteroids using ei-
ther a I-g "pulse" dose or a R~y tapering of the meth-
ylprednisolone dose. Corticosteroid-resistant rejection 
was treated with intravenous OKT3 monoclonal anti-
body (Ortho Phannaceuticals Co., Raritan, New Jersey). 
Variables Analyzed 
Exposures were ascertained up to the day of the first 
positive Candida blood culture among case patients (i.e., 
first day of candidemia) and at the corresponding follow-
up interval among control patients. The variables com-
pared between case patients and the matched control pa-
tients have been used in an earlier analysis of fungal 
infection after liver transplantation. 17 The variables ana-
lyzed can be classified into the following categories: 
I) demographic: sex. age. liver disease (hepatocellular. 
cholestatic. others): 2) surgical: number of transplant-
ations. total surgical time. abdominal surgery performed 
up to I week before candidemia, type of biliary anasto-
mosis: 3) nosocomial: duration of stay in the intensive 
care unit: number of days of exposure to total parenteral 
nutrition Eqm~F; use of urinary catheter. endotracheal 
tube. hemodialysis. and central lines and number of cen-
trallines: 4) antimicrobials: number of days of exposure 
to intravenous antibiotics: exposure to fewer or more 
than 3 different antibiotics (median number of antibiot-
ics received for case and control patients) for more than 
I day; duration of exposure to vancomycin or third-gen-
eration cephalosporins: and prophylaxis with trimetho-
prim-sulfamethoxazole, mycostatin. and amphotericin 
B; 5) immunosuppressive therapy: exposure to tacroli-
mus. cyclosporine. azathioprine and OKT3 and number 
of corticosteroid boluses; 6) amount of blood products 
given: red blood cells. fresh-frozen plasma. platelets; 
7) laboratory values before transplantation and at devel-
opment of candidemia, including white blood cell count. 
hematocrit. platelet count. albumin. creatinine. alanine 
aminotransferase. aspartate aminotransferase. total bili-
rubin, alkaline phosphatase. and prothrombin time; 
8) others: hyperglycemia requiring insulin therapy oc-
curring after transplantation and up to 2 weeks before 
Nn. Surg .• ....., 1911 
candidemia. and other infections that developed before 
candidemia. 
Because cultures for fungi were not obtained syste-
matically. Candida colonization was not included 
among the variables analyzed. 
Statistical Analysis 
Conditional linear logistic regression was used to iden-
tify risk factors for candidemia. and the odds ratio (OR) 
was computed as an estimate of the relative risk. IS An 
odds ratio greater than I suggested increased risk, 
whereas an odds ratio less than I suggested a protective 
effect. The interpretation of the odds ratio depends on 
the scale of measurement of the exposure. For exposures 
defined on a continuous scale (e.g .. age), the odds ratio 
indicates the change in the odds of disease for an increase 
of I unit in the exposure. For exposures defined on a 
nominal scale (e.g .• sex), the odds ratio indicates the odds 
of disease in the exposed group relative to the unexposed 
group. The analysis was done in two stages. First. univar-
iate analyses were performed to identifY candidate risk 
factors for candidemia. These factors were entered into a 
multivariate analysis if the probability value was less 
than 0.25. 19 Second. a stepwise multivariate conditional 
logistic regression (forward inclusion method) was used 
to assess simultaneously the effect of each exposure and 
to identify those lactors that are independently associ-
ated with c:mdidemia. The score was used to assess the 
importance of each factor at each stepwise run. The sta-
tistical significance level required for inclusion was set at 
0.05. The analyses were performed with use oithe statis-
tical software package EGRET.:o Kahn's method was 
used to compute approximate 95% confidence intervals 
(Cl) for unadjusted as well as adjusted odds ratios.21 
Patient survival was calculated from the date of the 
tirst orthotopic liver transplantation until death. and cu-
mulative survival rates were calculated with the Kaplan-
Meier (product-limit) method. Univariate Cox's propor-
tional hazards model was used to identify factors with 
potential prognostic significance and to calculate the rel-
ative risk (RR) of death. The outcome of interest was 
death associated with candidemia. Those deaths not as-
sociated with candidemia were censored at time of fail-
ure but were included with patients who survived for es-
timation of overall survival. On the basis of univariate 
analyses, a multivariate stepwise Cox's regression (for-
ward-inclusion method) was performed to identify those 
factors independently associated with candidemia-re-
lated mortality. 
RESULTS 
Clinical Findings 
Between December 1985 and December 1992, candi-
demia developed in 36 of the 2621 patients ( 1.4%) who 
]"' 
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Table 1. CLINICAL PRESENTATION 
(26 CASES) 
Pnmary candidemla 
PentonltiS 
Wound Infection 
Kidney fungus ball 
Line sepSIS 
AbdorrllnaJ abscess 
No. (%) 
4 (15) 
12 (46) 
1 (4) 
1 (4) 
5 (19) 
3 (12) 
• 
underwent liver transplantation at our institution. Com-
plete medical records were available for the 26 case pa-
tients. The most common isolate found was C. albicans 
(19 patients [73% D. The other isolates included C. gla-
brata (3 patients). C. tropicalis (I), C. stellato idea (I), C. 
pseudotropicalis ( I ), and C. parapsilosis ( I). Candidemia 
- was diagnosed at a median of 25 days after transplanta-
tion (range, 2-1690 days) and in 12 patients (46%) devel-
oped more than 1 month after transplantation. For 10 
patients. Candida species were isolated from the blood 
for more than I day (38%). Only 2 of 24 case patients 
(8%) who were examined by an ophthalmologist devel-
oped Candida endophthalmitis. No significant differ-
ence was observed in number of deaths between case pa-
tients who developed candidemia secondary to C. albi-
cans (84%) and those with other isolates (71%). 
Candidemia was treated in all cases with 0.5 to 0.7 mg/ 
kg/day amphotericin B administered intravenously to a 
cumulative dose 01 I to 2 g. 
Table I shows the clinical source of infection. Most 
candidemia episodes originated from intra-abdominal 
infections (58%), usually secondary to peritonitis, or 
from infected intravenous lines (19%). Four patients 
( 15%) had primary candidemia without an identified sec-
ondary site ofinfection. Candida species identical to that 
found in the blood were isolated before development of 
candidemia in 20 patients (77%) at a median of two other 
colonizing sites (range, I to 8) and at a median of9 days 
(range, I to 424 days) before fungemia. 
Twenty-one case patients (81 %) died at a median of 12 
days (range, 3"{) 15 days) after development of candide-
mia. Eleven of these patients had an autopsy performed 
(52%), and the results showed evidence of invasive can-
didiasis in nine cases (82%). Six patients who died up to 
2 weeks after development of candidemia did not have 
an autopsy performed. Therefore. a total of 15 deaths 
(71 %) were associated with candidemia. Figure I shows 
the time of diagnosis of candidemia and patient survival 
after transplantation. Nine cases of candidemia (35%) 
developed up to 2 weeks after liver transplantation and 
were associated with a 100% mortality rate. In three of 
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five survivors (60%), the cause of candidemia was a line 
sepsis. 
Factors Associated with the Development 
of Candidemia 
Twenty-one variables were found to be eligible for a 
multivariate analysis by our criterion (p < 0.25), as fol-
lows: female sex, more than one liver transplantation, 
undergoing abdominal surgery up to I week before can-
didernia. duration of total surgical time. duration of stay 
in the intensive care unit, duration of exposure to a uri-
narv catheter. duration of exposure to central venous 
lin~K duration of exposure to a respirator. number of 
days receiving dialysis, duration of TPN therapy, 
exposure to more than three different antibiotics admin-
istered intravenously, number of days of intravenous an-
tibiotic use, use of amphotericin B prophylaxis, use of 
tacrolimus. use of azathioprine. use ofOKT3. higher cre-
atinine levels before transplantation, higher bilirubin 
levels before transplantation. hyperglycemia developing 
up to 2 weeks before development of candidemia, hyper-
glycemia developing at or immediately after transplanta-
tion, and previous infections. 
Five of the 52 control patients ( 10%) and 9 of the 26 
case patients (35%) received prophylaxis with low-dose 
amphotericin B ( 10-20 mg/day). The use of amphoteri-
cin B prophylaxis was found to be associated with the 
development of candidemia. However. because the deci-
sion to use this prophylaxis was based on clinical suspi-
cion. it was not included in the multivariate analysis. 
This was done to avoid a selection bias in the estimation 
of the odds ratio. 
Table 2 shows the variables found to be simulta-
neously associated with candidemia in a multivariate 
analysis. These variables were hyperglycemia requiring 
insulin treatment occurring up to 2 weeks before devel-
opment ofcandidemia (OR = 16.15; 95% CI = 2.77-
94.07; P = 0.002) and use of more than three different 
antibiotics administered intravenously before develop-
ment of candidemia (OR = 11.15; 95% CI = 2.04-61.02; 
p = 0.005). 
Predictors of Candidemia-Related Death 
We identified predictors of candidemia-related death 
by comparing cases of death related to candidemia (n = 
IS) with cases of death not related to candidemia (n = 6) 
and with survivors (n = 5). The variables significant in 
the univariate analysis were entered into a multivariate 
Cox's regression analysis. These variables were total 
hours of surgery; abdominal surgery performed up to 1 
week before candidemia; and the number of days of 
exposure to central venous lines, urinary catheters. and 
,.' 
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Figure 1. rme of occurrence of can-
didemia and actuanaI patient SUMVal 
(KapIan-Meter) after liver transplanta· 
tion in patients WIth candideml8 and In 
the entire cohort. 
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antibiotics. With the development of candidemia, the 
variables were white blood cell count, hematocrit. plate-
let count. aspartate aminotransferase. alanine amino-
transferase. alkaline phosphatase. and prothrombin 
time. However. the only variables associated with death-
related candidemia according to the multivariate analy-
sis were abdominal surgery perfonned up to I week be-
fore candidemia (RR = 7.25; 95% CI = 1.36-38.64; p = 
0.02), high white blood cell count at diagnosis of candi-
demia (RR = 1.1; 95% CI = 1.02-1.19; P = 0.0 I), lower 
platelet count at candiderma (RR = 0.988; 95% CI = 
0.978--0.998; p = 0.02), and elevated aspartate amino-
transferase at candidemia (RR = 1.00 1; 95% CI 
1.0008-1.00 i 1; p = 0.01) (Table 2). 
DISCUSSION 
This study confirms previous reports suggesting that 
in immunocompromised patients even an isolated epi-
sode of candidemia should not be considered a benign 
transient condition. Two patients with isolated candide-
mia and with no evidence of previous colonization died 
within 14 days of developing candidemia. For one of 
these patients, the autopsy results showed disseminated 
Table 2. FACTORS ASSOCIATED WITH CANDIDEMIA AND 
CANDIDEMIA RELATED MORTAUTY 
Variable 
CandlderOia 
Hyperglycemia within 2 weeks of candidemla 
Exposure to more than three antibIOtics 
Candidemia Mortality 
Abdomlf13f surgery WIthIn 1 week before 
candldemia 
W8C at candiderrlla 
Platelet COUlt at candideml8 
AST at candidemia 
wee 2 wIlrte biood cell count: AST ~ asoartale amlT1Oltansterase. 
Odds 
Ratio 
16.15 
11.15 
Relative 
Risk 
7.25 
1.1 
0.988 
1.001 
95% Contlctenc:e 
Interval 
Lower Upper 
2.n 94.07 
2.04 61.02 
1.36 38.64 
1.02 1.19 
0.978 0.988 
1.0008 1.CX)11 
p-Value 
0.002 
0.005 
0.02 
0.01 
0.02 
0.01 
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candidiasis. Intra-abdominal infection, particularly perit 
toni tis, was the most common source of candidemia af-
ter orthotopic liver transplantation, thus suggesting that 
surgical complications play an important role in its ori-
gin. Additionally, our study showed the difficulty in 
making the diagnosis of invasive candidiasis. Candida 
endophthalmitis has been considered to be a marker of 
dissemination in nonimmunosuppressed patients.2U3 
However, only 8% of our patients with candidemia who 
had undergone an eye examination had endophthal-
mitis. These data correlate with experimental studies 
that have demonstrated a decreased incidence of oph-
thalmoscopicaly detectable endophthalmitis with im-
munosuppressive therapy.24 In these conditions, the in-
flammatory response is minimal, as has been shown in 
patients with acquired immunodeficiency syndrome 
who may have disseminated mycoses with only mild or 
no clinical symptoms. 25 
Hyperglycemia that required insulin treatment was 
one of two factors found to be associated with develop-
ment of candidemia after liver transplantation. Diabetes 
mellitus has been identified as an important underlying 
condition in Candida infections. from mucocutaneous 
infection to invasive disease.6.26.27 Our study confirms 
earlier observations that hyperglycemia influences the 
development of candidemia. 11..c8 Hyperglycemia is 
thought to impair several nonspecific mechanisms of the 
host defense29 ana to increase virulence of C. albicans. 
In a hyperglycemic environment. C. albicans overex-
presses a C3-receptor-like protein that impairs phago-
cytic recognition and promotes the adhesion of the fun-
gus to endothelial. mucosaL or foreign surfaces.30 
The cause of hyperglycemia development after liver 
transplantation is multifactorial and may be due to glu-
cocorticoidtherapy, stress of surgery, TPN. cyclospor-
ine, or tacrolimus. J1 Total parenteral nutrition therapy 
had been directly associated with the development of 
Candida endophthalmitis and candidemia, 28.32.33 partic-
,ularly among patients who have received broad-spec-
trum antibiotics. 21 However, in recent studies research-
ers could not demonstrate a direct association between 
TPN and candidemia.7-9·34 It was assumed that the asso-
ciation between TPN and candidemia was secondary to 
the use of central venous catheters. rather than to TPN 
per se. 9.35 However. none of these studies included hy-
perglycemia as a variable in the analysis of possible fac-
tors associated with candidemia. In our study, 65% of 
patients who developed candidemia and who were re-
ceiving TPN required insulin. in contrast to 27% of con-
trol patients. No significant difference was found be-
tween the case and control patients, in the number of 
patients who received TPN but not insulin, and the be-
tween the number of patients who received insulin but 
not TPN. This suggests that hyperglycemia requiring in-
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sulin is a key factor in the development of candidemia 
during TPN therapy. 
The number of antibiotics given intravenously as well 
as longer treatment courses of antibiotics has been ass0-
ciated with development of candidemia. 7-9 In our study, 
only the number of antibiotics administered was associ-
ated with development of candidemia. It had been estab-
lished that the use of broad-spectrum antibiotics, partic-
ularly those that inhibit gram-negative anaerobic bacte-
ria, results in a substantially greater concentration of 
Candida species in the gUt.36 The administration of three 
or more antibiotics to our patients most likely markedly 
reduced the anaerobic gut flora. We recently demon-
strated that candidates for liver transplantation are have 
high yeast colonization in the gut before transplanta-
tion. 37 When these patients with yeast colonization in 
their gut received broad-spectrum antibiotics after trans-
plantation. Candida colonization increased even fur-
ther. 
The mortality rate associated with candidemia was 
71 %. which is higher than that recently reported in a 
study of patients with cancer (42%) that covered a similar 
time period. 15 The most important predictor of candide-
mia-related death was abdominal surgery performed up 
to I week before development of candidemia. Possibly, 
bowel manipulation during abdominal surgery of pa-
tients with heavy colonization releases large amounts of 
yeast into the bloodstream. This may produce a more 
intense inflammatory response. resulting in a more se-
vere disease and death.J8 
Although amphotericin B is still considered the drug of 
choice for treatment of invasive candidiasis, its toxicity is 
a significant limitation. Auconazole, a triazole. has re-
cently been found to be effective for the treatment of can-
didemia in patients without major immunodeficiency 
and without neutropenia.39 Additional comparative tri-
als are needed to study the effectiveness of fluconazole 
among immunosuppressed patients. 
In summary, candidemia is associated with a high 
mortality rate in liver transplant recipients, particularly 
when it occurs shortly after abdominal operations. We 
identified two factors associated with the development 
of candidemia: treatment with multiple antibiotics and 
hyperglycemia requiring insulin. Therapeutic modalities 
to be evaluated in prospective trials should include the 
use of higher doses of amphotericin B prophylaxis and 
the use of new antifungal agents for prophylaxis. 
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